Chad Wadell, MD
Internal Medicine · Mission Viejo, CANPI 1144436262
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.3% of the total across 168 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 32 manufacturers, the largest accounting for just 16.9% — the pattern of someone who eats at a lot of different presentations.
Across 168 payments — averaging $21.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$617
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$353
- Novartis$285
- AstraZeneca$224
- Pfizer$215
- Astellas Pharma US Inc$195
- plus $2K from 26 others
Across 8 payments — averaging $10,917 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$87K
What the payments were for
- Consulting fees$251%
- Food & beverage$3,62899%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 27 | $617 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 10 | $353 |
| Novartis | 8 | $285 |
| AstraZeneca | 6 | $224 |
| Pfizer | 36 | $215 |
| Astellas Pharma US Inc | 12 | $195 |
| Amgen | 9 | $185 |
| Novo Nordisk | 8 | $155 |
| NEW World Medical,inc. | 1 | $147 |
| Edwards Lifesciences | 2 | $147 |
| AbbVie(2 entities) | 7 | $129 |
| Intuitive Surgical | 1 | $126 |
| Inari Medical, Inc. | 2 | $123 |
| Lilly USA, LLC | 6 | $104 |
| Johnson & Johnson | 6 | $103 |
| GSK | 4 | $72 |
| Sanofi-aventis U.S. LLC | 3 | $59 |
| Exact Sciences | 2 | $55 |
| Sanofi Pasteur Inc. | 2 | $42 |
| IBSA Pharma Inc. | 1 | $39 |
| Verity Pharmaceuticals Inc. | 2 | $38 |
| Merck | 2 | $36 |
| Boston Scientific | 2 | $29 |
| Almatica Pharma LLC | 1 | $27 |
| Gilead | 1 | $25 |
| Bayer | 1 | $24 |
| Regeneron Healthcare Solutions, Inc. | 1 | $21 |
| Teva Pharmaceuticals USA, Inc. | 1 | $20 |
| Antares Pharma, Inc. | 1 | $19 |
| Sumitomo Pharma America, Inc. | 1 | $17 |
| Therapeuticsmd, Inc. | 1 | $13 |
| Endogastric Solutions, Inc | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,653 in reported general payments places this provider in the 85th percentile of 13,581 internal medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 59 | $78,968 |
| EliquisApixaban | 63 | $63,369 |
| OzempicSemaglutide | 48 | $56,608 |
| Repatha SureclickEvolocumab | 52 | $55,660 |
| MounjaroTirzepatide | 47 | $48,064 |
| XareltoRivaroxaban | 20 | $30,485 |
| MyrbetriqMirabegron | 22 | $28,272 |
| TrulicityDulaglutide | 12 | $23,022 |
| Repatha SyringeEvolocumab | 15 | $18,763 |
| LinzessLinaclotide | 19 | $14,861 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 18 | $11,675 |
| Spiriva HandihalerTiotropium Bromide | 11 | $10,726 |
| Atorvastatin Calcium | 873 | $9,159 |
| SynthroidLevothyroxine Sodium | 86 | $7,740 |
| Levothyroxine Sodium | 339 | $4,762 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $617 | $78,96859 claims |
| Lilly USA, LLCMounjaro, Trulicity | $104 | $71,08659 claims |
| PfizerEliquis | $215 | $63,36963 claims |
| Novo NordiskOzempic | $155 | $56,60848 claims |
| Johnson & JohnsonXarelto | $103 | $30,48520 claims |
| Astellas Pharma US IncMyrbetriq | $195 | $28,27222 claims |
| AbbVieLinzess, Synthroid | $129 | $22,601105 claims |
| GSKTrelegy Ellipta | $72 | $11,67518 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 13,581 internal medicine providers in California.
Other internal medicine in Mission Viejo
- Andrew ChengSouth San Francisco$55.1M
- Tung NgoNewport Beach$4.9M
- Christian EversullStanford$2.9M
- Christian SandrockSacramento$2.1M
- Hatim HusainSan Diego$2M
- Teck LingPalo Alto$1.1M
- Hyong Kimla Jolla$1M
- Rohit Loombala Jolla$965K
- Fred CohenSan Francisco$929K
- Steven EdelmanSan Diego$863K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.